glp-1 logo Discover How Trials Are Not One-Size-Fit-All GLP-1 Weight Loss in New

GLP-1 Receptor Agonist Market Insights, By Drug Class: Liraglutide Contributes the Highest Share of the Market Owing to its Effectiveness and Superior Efficacy In terms of drug type, liraglutide is expected to contribute 26.5% share of the market in 2026, as its once-daily subcutaneous administration provides consistent glycemic control throughout the day

Over time, patients often report that hunger gradually returns or that food cravings become harder to ignore

Thymic Stromal Lymphopoietin Activation of Basophils in Patients with Allergic Asthma Is IL-3 Dependent

Due to low skin tolerability, 3 patients discontinued the trial

Potential Benefits & Side Effects Observations from limited and dated preclinical and clinical literature